Contrasting Kiora Pharmaceuticals (NASDAQ:KPRX) and Jaguar Animal Health (NASDAQ:JAGX)

Jaguar Animal Health (NASDAQ:JAGX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Profitability

This table compares Jaguar Animal Health and Kiora Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-187.88%	N/A	-131.45%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Analyst Recommendations

This is a summary of recent recommendations for Jaguar Animal Health and Kiora Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1	0	0	0	1.00
Kiora Pharmaceuticals	1	0	0	0	1.00

Institutional and Insider Ownership

12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.2% of Jaguar Animal Health shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Jaguar Animal Health has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.22, suggesting that its share price is 122% less volatile than the S&P 500.

Valuation and Earnings

This table compares Jaguar Animal Health and Kiora Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$11.51 million	0.11	-$53.43 million	($3,731.33)	-0.00
Kiora Pharmaceuticals	$16.02 million	0.71	-$10.84 million	($2.51)	-1.02

Kiora Pharmaceuticals has higher revenue and earnings than Jaguar Animal Health. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Summary

Kiora Pharmaceuticals beats Jaguar Animal Health on 8 of the 11 factors compared between the two stocks.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.